Emergent Biosolutions doubled the size of its manufacturing facility in Bayview earlier this year. With an acquisition deal announced Wednesday, the life sciences company now has plans for the primary product that will be made there.

The Gaithersburg-based multinational is set to purchase an anthrax treatment from pharmaceutical giant GlaxoSmithKline in a deal that could be worth up to $96 million.

EBS is purchasing raxibacumab, an FDA-approved drug that treats inhaled anthrax. It already has the attention of the U.S. government. The deal also includes a federal contract to manufacture the antidote for the U.S. National Stockpile, which the country keeps in case of emergency.

READ FULL ARTICLE HERE